Press release
United States Oral Anti-Diabetes Market to hit US$ 80.8 billion by 2031 |Top companies - Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis
Oral Anti-Diabetes Market
United States: Recent Industry Developments
October 2025
✅ Eli Lilly received FDA approval for its oral once-weekly GLP-1 agonist, Orforglipron, marking a breakthrough in type 2 diabetes care. This innovation offers injectable-level efficacy in tablet form, expanding access and patient comfort. It positions Lilly as a frontrunner in next-generation oral incretin therapies.
September 2025
✅ Pfizer launched a fixed-dose combo of Empagliflozin + Metformin XR in the U.S. to simplify diabetes treatment. The single-tablet regimen aims to improve adherence and glycemic control in type 2 diabetes patients. This move strengthens Pfizer's footprint in the growing oral anti-diabetic drug market.
August 2025
✅ Merck & Co. expanded U.S. production of Januvia (Sitagliptin) to meet rising demand for DPP-4 inhibitors. The expansion supports domestic supply resilience amid increasing diabetes prevalence. It reflects Merck's ongoing investment in scaling capacity for chronic disease therapies.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/oral-anti-diabetes-drugs-market?sindhuri
Japan: Recent Industry Developments
October 2025
✅ Japan witnessed rising momentum in the incretin therapy space, with pharma firms preparing for next-gen oral GLP-1 and dual GIP/GLP-1 agonists.
Collaborations between local and global companies advanced metabolic and obesity-related treatment portfolios. The focus shifted toward expanding access to innovative diabetes and weight management solutions.
September 2025
✅ Japan approved Finerenone (Kerendia®) for adults with chronic kidney disease and type 2 diabetes, broadening cardio-renal treatment options. The market also saw strategic collaborations promoting GLP-1-based therapies for obesity and metabolic disorders.These developments underscore Japan's expanding commitment to comprehensive diabetes management.
August 2025
✅ While no major oral diabetes drug launches occurred, clinical progress continued for advanced oral GLP-1 therapies under review. Pharma leaders focused on optimizing treatment strategies for ageing and renal-impaired diabetic populations. The month reflected strong research activity ahead of anticipated late-2025 product introductions.
Asia-Pacific: Recent Industry Developments
October 2025
✅ Novo Nordisk A/S initiated Phase 3 trials in China for its next-generation oral semaglutide 2.0 formulation, designed to enhance bioavailability and patient convenience. This advanced version aims to deliver greater efficacy with a smaller dose, minimizing gastrointestinal side effects. The trial reflects Novo Nordisk's continued leadership in expanding oral GLP-1 innovation across the Asia-Pacific region.
September 2025
✅ Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved Boehringer Ingelheim's fixed-dose combination (FDC) of Empagliflozin + Linagliptin. The approval supports cardiovascular risk reduction in patients with type 2 diabetes, beyond glycemic control. This marks a major milestone in Japan's regulatory progress for combination oral therapies with proven heart health benefits.
August 2025
✅ AstraZeneca PLC entered a strategic partnership with a South Korean biotech firm to co-develop a dual GIP/GLP-1 oral agonist. The collaboration focuses on advancing next-generation incretin-based drugs tailored for Asia-Pacific markets. This partnership strengthens AstraZeneca's R&D presence in metabolic diseases, targeting broader diabetes and obesity management solutions.
Market Trends & Drivers
The Global Oral Anti-Diabetes Drugs Market is witnessing robust growth fueled by the escalating prevalence of type 2 diabetes, expanding geriatric population, and rising adoption of combination therapies for better glycemic control. Key trends include the shift toward novel oral GLP-1 agonists and SGLT2 inhibitors, increasing penetration of generics in emerging markets, and growing preference for fixed-dose combinations (FDCs) to enhance patient compliance. The surge in lifestyle-related diabetes, advancements in drug delivery (e.g., extended-release formulations), and supportive government initiatives for affordable diabetes care are significantly propelling market expansion.
Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/oral-anti-diabetes-drugs-market?sindhuri
Competitive Landscape
The market exhibits fierce competition among multinational pharmaceutical giants, generic manufacturers, and innovative biotech firms.
1. Glenmark Pharmaceuticals Ltd. strengthens its leadership in affordable oral anti-diabetic generics and fixed-dose combinations (FDCs), with a strong presence across Asia, Africa, and Latin America, driving access in emerging markets.
2. Abbott Laboratories maintains a solid position with its comprehensive diabetes care portfolio including oral anti-diabetic formulations and glucose monitoring solutions, supported by strong physician outreach and patient awareness programs.
3. Biocon Ltd. advances in biosimilar and novel oral formulations for diabetes, focusing on cost-effective therapies and partnerships to expand accessibility in developing regions.
4. Sanofi S.A. dominates the sulfonylurea and combination drug markets through legacy brands like Amaryl and continues to strengthen its diabetes franchise with new-generation oral formulations and expanding global footprint.
5. Sun Pharmaceutical Industries Ltd. leverages large-scale, cost-efficient production of metformin-based and DPP-4 inhibitor generics, reinforcing its position as a key supplier across developed and emerging markets.
6. Novartis AG continues to expand its Galvus (vildagliptin) and related combination therapies, backed by strong cardiovascular outcomes data and regional market partnerships in Europe and Asia-Pacific.
7. Novo Nordisk A/S leads innovation with Rybelsus (oral semaglutide) and a strong pipeline of next-gen oral GLP-1 analogs, setting new standards in first-line Type 2 diabetes management.
8. Merck & Co., Inc. remains a global leader in DPP-4 inhibitors with its Januvia and Janumet franchise, while investing in advanced fixed-dose combinations to enhance glycemic and cardiovascular outcomes.
9. GlaxoSmithKline plc (GSK) focuses on research-driven innovation and strategic alliances to develop novel oral anti-diabetic agents and improve adherence through convenient dosage forms and combination options.
10. Bristol-Myers Squibb Company-in collaboration with AstraZeneca PLC-continues to drive growth in SGLT2 inhibitors through its Dapagliflozin (Farxiga) franchise, reinforcing leadership in cardiorenal-focused diabetes care.
Buy now and enjoy a 30% year-end discount - limited-time offer!
https://www.datamintelligence.com/buy-now-page?report=oral-anti-diabetes-drugs-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)
Segmentation
» By Drug Class
The Oral Anti-Diabetes Drugs Market is segmented by drug class into Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides. Each class targets glucose regulation through distinct mechanisms, supporting treatment personalization for patients with Type 2 Diabetes.
» By Dosage Type
Based on dosage type, the market is divided into Liquid, Capsule, and Tablet forms. Tablets remain the most widely used format owing to convenience, dosage accuracy, and cost-effectiveness, while liquid formulations are preferred for patients with swallowing difficulties.
» By Distribution Channel
Distribution channels include Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital and retail pharmacies dominate due to prescription-based purchases, whereas online pharmacies are rapidly expanding with the rise of digital health platforms and home delivery services.
Regional Analysis
» The Oral Anti-Diabetes Drugs Market is geographically divided into North America, South America, Europe, Asia Pacific, the Middle East, and Africa. North America leads the market due to high diabetes prevalence and strong healthcare infrastructure.
» Europe follows with steady growth driven by government awareness programs and access to novel oral therapies. The Asia Pacific region is projected to witness the fastest growth, fueled by increasing urbanization, rising diabetic population, and expanding pharmaceutical investments.
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription
✅ Competitive Landscape
✅ Patent Expiry & Generic Entry Analysis
✅ Combination Therapy Adoption Trends
✅ KOL / ADA Guideline Insights
✅ Patient Adherence & Affordability Shifts
✅ API Sourcing & Supply Chain Dynamics
✅ Live Pricing & Reimbursement Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Oral Anti-Diabetes Market to hit US$ 80.8 billion by 2031 |Top companies - Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis here
News-ID: 4259131 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Frozen Fruits Market Surges Toward US$6.54 Billion by 2030 - Asia-Pacific Leads …
According to DataM Intelligence, the global frozen fruits market size was valued at US$3,957.4 million in 2022 and is forecasted to reach US$6,549.4 million by 2030, growing at a CAGR of 6.5% from 2024 to 2031. This steady growth is propelled by rising health consciousness among consumers, increasing demand for convenient and nutritious food options, expanding food processing and service sectors, growing preference for organic and plant-based products, surging popularity…
United States Feed Testing Market Booms on 6.50% CAGR - North America Dominates …
According to DataM Intelligence, the global feed testing market size was valued at US$3.50 billion in 2024 and is forecasted to reach US$5.70 billion by 2031, growing at a CAGR of 6.50% during the forecast period (2024-2031). This steady growth is propelled by stringent regulatory standards for animal feed safety, rising demand for high-quality meat and dairy products, increasing livestock production, growing pet food safety concerns, and expanding focus on…
United States Sugar Decorations & Inclusions Market Surges on 5.80% CAGR - Custo …
According to DataM Intelligence, the global sugar decorations and inclusions market size was valued at US$2.15 billion in 2023 and is forecasted to reach US$3.45 billion by 2030, growing at a CAGR of 5.80% from 2023 to 2030. This steady growth is propelled by rising demand for personalized baked goods, expanding bakery and confectionery sectors, increasing consumer preference for visually appealing desserts, growth in organized retail for convenience foods, and…
Aluminum Extrusion Industry Forecast 2025-2031: Rising Demand in Automotive and …
Global Aluminum Extrusion Market reached US$ 78.7 billion in 2022 and is expected to reach US$ 117.8 billion by 2030, growing with a CAGR of 5.7% during the forecast period 2025-2031.
According to DataM Intelligence has published a new research report on "Aluminium Extrusion Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
